ProPhase Labs Statistics
Total Valuation
ProPhase Labs has a market cap or net worth of $59.52 million. The enterprise value is $81.07 million.
| Market Cap | 59.52M |
| Enterprise Value | 81.07M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, before market open.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ProPhase Labs has 19.08 million shares outstanding. The number of shares has decreased by -0.09% in one year.
| Shares Outstanding | 19.08M |
| Shares Change (YoY) | -0.09% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 17.47% |
| Owned by Institutions (%) | 9.10% |
| Float | 15.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.07 |
| Forward PS | 0.77 |
| PB Ratio | 1.33 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.88, with a Debt / Equity ratio of 0.52.
| Current Ratio | 1.88 |
| Quick Ratio | 1.54 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -19.44 |
Financial Efficiency
Return on equity (ROE) is -45.00% and return on invested capital (ROIC) is -45.16%.
| Return on Equity (ROE) | -45.00% |
| Return on Assets (ROA) | -25.90% |
| Return on Capital (ROIC) | -45.16% |
| Revenue Per Employee | $254,115 |
| Profits Per Employee | -$208,823 |
| Employee Count | 113 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 5.81 |
Taxes
| Income Tax | -8.60M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.26% in the last 52 weeks. The beta is -0.09, so ProPhase Labs's price volatility has been lower than the market average.
| Beta (5Y) | -0.09 |
| 52-Week Price Change | -57.26% |
| 50-Day Moving Average | 4.43 |
| 200-Day Moving Average | 4.85 |
| Relative Strength Index (RSI) | 24.07 |
| Average Volume (20 Days) | 32,759 |
Short Selling Information
The latest short interest is 322,273, so 1.69% of the outstanding shares have been sold short.
| Short Interest | 322,273 |
| Short Previous Month | 320,787 |
| Short % of Shares Out | 1.69% |
| Short % of Float | 2.05% |
| Short Ratio (days to cover) | 10.42 |
Income Statement
In the last 12 months, ProPhase Labs had revenue of $28.72 million and -$23.60 million in losses. Loss per share was -$1.36.
| Revenue | 28.72M |
| Gross Profit | 5.29M |
| Operating Income | -30.80M |
| Pretax Income | -32.20M |
| Net Income | -23.60M |
| EBITDA | -23.50M |
| EBIT | -30.62M |
| Loss Per Share | -$1.36 |
Balance Sheet
The company has $1.79 million in cash and $23.34 million in debt, giving a net cash position of -$21.54 million or -$1.13 per share.
| Cash & Cash Equivalents | 1.79M |
| Total Debt | 23.34M |
| Net Cash | -21.54M |
| Net Cash Per Share | -$1.13 |
| Equity (Book Value) | 44.87M |
| Book Value Per Share | 2.35 |
| Working Capital | 21.14M |
Cash Flow
In the last 12 months, operating cash flow was -$16.94 million and capital expenditures -$3.53 million, giving a free cash flow of -$20.47 million.
| Operating Cash Flow | -16.94M |
| Capital Expenditures | -3.53M |
| Free Cash Flow | -20.47M |
| FCF Per Share | -$1.14 |
Margins
Gross margin is 18.41%, with operating and profit margins of -107.27% and -82.18%.
| Gross Margin | 18.41% |
| Operating Margin | -107.27% |
| Pretax Margin | -112.12% |
| Profit Margin | -82.18% |
| EBITDA Margin | -81.85% |
| EBIT Margin | -106.63% |
| FCF Margin | -71.30% |
Dividends & Yields
ProPhase Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.09% |
| Shareholder Yield | 0.09% |
| Earnings Yield | -39.64% |
| FCF Yield | -34.40% |
Analyst Forecast
The average price target for ProPhase Labs is $11.00, which is 252.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.00 |
| Price Target Difference | 252.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 23, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 23, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ProPhase Labs has an Altman Z-Score of 0.09 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.09 |
| Piotroski F-Score | 1 |